Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
620
archived clinical trials in
ADHD

An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)
An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)
An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Vyvanse Driving Study
The Effects of Vyvanse on the Driving Performance of Young Adults With ADHD: A Randomized, Double-Blind, Placebo-Controlled Study
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Vyvanse Driving Study
The Effects of Vyvanse on the Driving Performance of Young Adults With ADHD: A Randomized, Double-Blind, Placebo-Controlled Study
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine Medical Center
mi
from
Orange, CA
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)
Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence
Status: Enrolling
Updated:  12/31/1969
Duke Child and Family Study Center//Duke Health Behavior Neuroscience Research Program
mi
from
Durham, NC
Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)
Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence
Status: Enrolling
Updated: 12/31/1969
Duke Child and Family Study Center//Duke Health Behavior Neuroscience Research Program
mi
from
Durham, NC
Click here to add this to my saved trials
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center LLC
mi
from
Maitland, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Janus Ctr. for Psychiatric Research
mi
from
Palm Beach, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Janus Ctr. for Psychiatric Research
mi
from
Palm Beach, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Carman Research
mi
from
Smyrna, GA
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Carman Research
mi
from
Smyrna, GA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Psychiatric Associates
mi
from
Overland Park, KA
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Adult ADHD Program
mi
from
New York, NY
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Adult ADHD Program
mi
from
New York, NY
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
IPS Research
mi
from
Oklahoma City, OK
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
IPS Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
mi
from
Portland, OR
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Lincoln Research
mi
from
Lincoln, RI
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Lincoln Research
mi
from
Lincoln, RI
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
CNS Healthcare of Memphis
mi
from
Memphis, TN
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
CNS Healthcare of Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
FutureSearch Clinical Trials
mi
from
Austin, TX
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
FutureSearch Clinical Trials
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Lifetree Clinical Research, LC
mi
from
Salt Lake City, UT
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Lifetree Clinical Research, LC
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Midwest Research Group
mi
from
Saint Charles, MO
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Midwest Research Group
mi
from
Saint Charles, MO
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Ctr. for Psychiatry & Behavioral Med.
mi
from
Las Vegas, NV
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Ctr. for Psychiatry & Behavioral Med.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Amiloride Hydrochloride as an Effective Treatment for ADHD
Amiloride Hydrochloride as an Effective Treatment for ADHD
Status: Enrolling
Updated:  12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
Amiloride Hydrochloride as an Effective Treatment for ADHD
Amiloride Hydrochloride as an Effective Treatment for ADHD
Status: Enrolling
Updated: 12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Nicotine, Non-Smokers With and Without ADHD, and Genetics Study
Nicotine, Non-Smokers With and Without ADHD, and Genetics Study
Status: Enrolling
Updated:  12/31/1969
Duke Child and Family Study Center
mi
from
Durham, NC
Nicotine, Non-Smokers With and Without ADHD, and Genetics Study
Nicotine, Non-Smokers With and Without ADHD, and Genetics Study
Status: Enrolling
Updated: 12/31/1969
Duke Child and Family Study Center
mi
from
Durham, NC
Click here to add this to my saved trials
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Initial Validation of the Vanderbilt ADHD Measure for Adolescent Patients in the ICISS Project
Initial Validation of the Vanderbilt Attention Deficit Hyperactive Disoder (ADHD) Measure for Adolescent Patients in the Integrated Clinical Information Sharing System (ICISS) Project
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital, Adolescent/ Young Adult Clinic
mi
from
Boston, MA
Initial Validation of the Vanderbilt ADHD Measure for Adolescent Patients in the ICISS Project
Initial Validation of the Vanderbilt Attention Deficit Hyperactive Disoder (ADHD) Measure for Adolescent Patients in the Integrated Clinical Information Sharing System (ICISS) Project
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital, Adolescent/ Young Adult Clinic
mi
from
Boston, MA
Click here to add this to my saved trials
Intervening Early With Neglected Children
Intervening Early With Neglected Children: Key Childhood Outcomes
Status: Enrolling
Updated:  12/31/1969
University of Delaware
mi
from
Newark, DE
Intervening Early With Neglected Children
Intervening Early With Neglected Children: Key Childhood Outcomes
Status: Enrolling
Updated: 12/31/1969
University of Delaware
mi
from
Newark, DE
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
AVIDA, Inc.
mi
from
Newport Beach, CA
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
AVIDA, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
Kennedy Krieger Institute
mi
from
Baltimore, MD
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
Center For Psychiatry and Behavioral Medicine In
mi
from
Las Vegas, NV
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
Center For Psychiatry and Behavioral Medicine In
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
Duke Child and Family Center
mi
from
Durham, NC
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
Duke Child and Family Center
mi
from
Durham, NC
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  12/31/1969
Houston Clinical Trials, LLC
mi
from
Houston, TX
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 12/31/1969
Houston Clinical Trials, LLC
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Harmonex Neuroscience Research
mi
from
Dothan, AL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Harmonex Neuroscience Research
mi
from
Dothan, AL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
NRC Research Institute
mi
from
Orange, CA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
PCSD - Feighner Research
mi
from
San Diego, CA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
PCSD - Feighner Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Encompass Clinical Research
mi
from
Spring Valley, CA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Elite Clinical Trials
mi
from
Wildomar, CA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Elite Clinical Trials
mi
from
Wildomar, CA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Sarkis Clinical Trials
mi
from
Gainesville, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Medical Research Group of Central Florida
mi
from
Orange City, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Medical Research Group of Central Florida
mi
from
Orange City, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Miami Research Associates
mi
from
South Miami, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Northwest Behavioral Research Center
mi
from
Marietta, GA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Northwest Behavioral Research Center
mi
from
Marietta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Capstone Clinical Research
mi
from
Libertyville, IL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials